Harnessing the power of protein expression systems in vaccine development

To combat urgent threats like the COVID-19 pandemic, vaccine developers actively seek the most efficient and robust production platforms to accelerate development timelines. The Gibco Expi Expression Systems enable rapid, high-yield, and scalable production of proteins, viral antigens and viral-like particles from mammalian (ExpiCHO and Expi293) and insect (ExpiSf) cells. By providing flexible and highly productive expression systems that employ optimized and chemically defined components, the Expi systems support every stage of vaccine development. This unified, end-to-end approach reduces key product quality risks while streamlining process development with integrated reagents. This webinar covers how researchers can harness the power of Expi protein expression systems to produce recombinant antigens for the development of vaccines and serological tests.